XAV‐939 treatment inhibited FGF9‐mediated β‐catenin signaling in Huh7 and HepG2 cells, thereby implying a strong correlation between FGF9 function and β‐catenin‐mediated NASH‐driven HCC. Here, FGF9 is linked to metabolic dysfunction-associated steatohepatitis.